Daniel H Solomon (@danielhsolomon) 's Twitter Profile
Daniel H Solomon

@danielhsolomon

Rheumatologist & epidemiologist at Brigham and Women's Hospital, Section of Clinical Sciences, and Professor of Medicine at Harvard Medical School.

ID: 373664020

linkhttp://scs.bwh.harvard.edu calendar_today15-09-2011 00:35:38

4,4K Tweet

2,2K Followers

669 Following

Rheumatology Research Foundation (@rheumresearch) 's Twitter Profile Photo

Joel Kremer, MD & Sara Kremer commit $1M to support early & mid-career rheumatology researchers! Their gift drives crucial research & inspires others to make a lasting impact. #rheumresearch Read the full press release at rheumresearch.org/newsroom

Rohit Aggarwal (@docrota) 's Twitter Profile Photo

Hot off the press: Most comprehensive analysis on Anti-Synthetase Syndrome (ASSD) is out. Paper by Akira Yoshida, Sara Kashani, Giovanni of CLASS in A&R. Stay tuned for 1st ever Classification Criteria of Anti-ASSD presented at #ACR2024 by Giovanni et al. acrjournals.onlinelibrary.wiley.com/doi/10.1002/ar…

American College of Rheumatology (@acrheum) 's Twitter Profile Photo

NEW EPISODE! What do antinuclear antibodies & immunologically active DNA have to do with the pathogenesis of #SLE? Let’s dive in with David S. Pisetsky, MD, PhD, HERE → acr.tw/3Ur1Ls2 ACR_Journals

NEW EPISODE! What do antinuclear antibodies &amp; immunologically active DNA have to do with the pathogenesis of #SLE? Let’s dive in with David S. Pisetsky, MD, PhD, HERE → acr.tw/3Ur1Ls2 <a href="/ACR_Journals/">ACR_Journals</a>
ACR_Journals (@acr_journals) 's Twitter Profile Photo

Trends in DMARD use for children with juvenile idiopathic arthritis from US commercial claims data 2000-2022: •csDMARD use declined 89.5% to 43.2% •bDMARD use increased 10.5% to 50% •adalimumab most commonly initiated b/tsDMARD at 20.5% in 2022 •after 1st csDMARD, adalimumab

Trends in DMARD use for children with juvenile idiopathic arthritis from US commercial claims data 2000-2022: 
•csDMARD use declined 89.5% to 43.2%
•bDMARD use increased 10.5% to 50%
•adalimumab most commonly initiated b/tsDMARD at 20.5% in 2022
•after 1st csDMARD, adalimumab
ACR_Journals (@acr_journals) 's Twitter Profile Photo

Using an int'l, multicenter database, this study identified clinical and serologic variables associated with anti-synthetase syndrome to aid in development of classification criteria In A&R acrjournals.onlinelibrary.wiley.com/doi/abs/10.100…

Using an int'l, multicenter database, this study identified clinical and serologic variables associated with anti-synthetase syndrome to aid in development of classification criteria

In A&amp;R
acrjournals.onlinelibrary.wiley.com/doi/abs/10.100…
ACR_Journals (@acr_journals) 's Twitter Profile Photo

Myeloid-derived suppressor cells (MDSCs) contribute to SLE pathogenesis. This study investigated whether FoxO1 deficiency in monocyte MDSCs enhances aberrant B cell function in lupus. Results suggest therapeutic potential of targeting ALKBH5/FoxO1/Met in monocyte MDSCs In A&R

Myeloid-derived suppressor cells (MDSCs) contribute to SLE pathogenesis. This study investigated whether FoxO1 deficiency in monocyte MDSCs enhances aberrant B cell function in lupus. Results suggest therapeutic potential of targeting ALKBH5/FoxO1/Met in monocyte MDSCs

In A&amp;R
ACR_Journals (@acr_journals) 's Twitter Profile Photo

New installment in the Arthritis & Rheumatology Immunology for the Rheumatologist review series: Macrophage activation syndrome acr.tw/4egVzdd

New installment in the Arthritis &amp; Rheumatology Immunology for the Rheumatologist review series:
Macrophage activation syndrome
acr.tw/4egVzdd
ACR_Journals (@acr_journals) 's Twitter Profile Photo

Meet the Editors of A&R, AC&R, and ACROR at #ACR24 Monday, Nov 18, 8AM in the Networking Lounge Ask about publishing rheum research or just drop in and say 'Hi'!

ACR_Journals (@acr_journals) 's Twitter Profile Photo

2024 editor's picks from A&R being presented at #ACR24 Sunday, Nov 17, 10:30AM~ Risk of Lung Cancer in RA and RA-ILD acr.tw/3NyPEFo Genetic and Clinical Risk Factors for Classifying Uveitis Risk in JIA acr.tw/4h9jiPn